Radiofrequency Ablation Devices Market Transforming Pain Management Scenario, says Market.us

Market growth is driven by the rise in patients with pain and cancer and cardiovascular diseases like atrial fibrillation. The use of RFAD ultrasound ablation technology makes these devices more popular. Due to the lack of awareness and high costs of treatment, the market is still small. According to estimates, drivers will have a greater impact than restraints.

According to the latest report by Market.us,” The global Radiofrequency Ablation Devices Market was valued at USD 3.9 billion in 2022 and is projected to reach USD 11.8 billion by 2032, at a CAGR of 11.7%.”

Anurag Sharma, senior research analyst at market.us said, The increasing preference of patients for minimally invasive procedures will influence market forecasts. Radiofrequency ablation devices market share is driven by patients’ preference for less invasive procedures than open surgeries. Minimally invasive procedures have enjoyed a steady increase in popularity and acceptance over the past few years.

Market growth will be driven mainly by rising osteoporosis rates and arthritis. In 2015, 15,000,000 Americans suffered from severe arthritis-related joint pain according to the U.S. Department of Health & Human Services. An estimated 78,000,000 Americans (26%) will be diagnosed as having arthritis by 2040.

Due to increasing atrial fibrillation prevalence, cardiac ablation procedures will continue to increase. The minimally invasive treatment of atrial fibrillation can be more effective, convenient, and less risky than a surgical procedure. Due to increasing adoption of ablation devices and minimally invasive treatments, the market for ablation devices will continue to grow.

The lack of reimbursement policies and a shortage of skilled staff are limiting industry growth. Insurance companies must make every effort to change existing reimbursement rules. Their growth can be impeded by a lack of policies regarding aesthetic treatments. Because these treatments can cause temporary swelling or burns, only qualified professionals should perform them. Due to the lack of qualified workers, this technology might not be widely adopted by end-users.

Rising treatment costs will limit market growth and increase the risk of cancer recurrence. The market will also be more complicated due to the burning sensation that is felt at the treatment site.

Given below are the recent developments in the Market:

• In May 2022: Huazhong University of Science and Technology has created a radiofrequency ablation method to heat only cancerous tissue and preserve healthy tissue.
• April 2022: IQWiG has now published an assessment of two 137h procedures that were commissioned by G-BA. The first involves an endoscopic ultrasound-guided 32P microscopically inserted pancreatic cancer treatment. Transcervical radiofrequency ablation with intrauterine ultrasound guidance is used to treat uterine fibroids.

North America will be the dominant market for tumor-ablation devices in the future, due to its rising incidence of cancer. The National Cancer Institute of the United States estimates that there will be 1.7 millions new cases of cancer in 2018. This will increase demand for North American tumor-ablation devices. This is combined to a growing geriatric population, and the increasing adoption of advanced technology.

North America’s growing healthcare infrastructure will be a major driver of the tumor ablation market. There is potential for tumor-ablation devices to be used in Asia Pacific and Middle East and Africa due to rising cancer rates and an increase in neoplastic diseases.